New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

INDIANAPOLIS, IN, USA I February 26, 2018 I Trulicity® (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, according to results from AWARD-10, a new Phase 3b clinical study.1 These data were published online first in The Lancet Diabetes & Endocrinology. Trulicity is Eli Lilly and Company's (NYSE: LLY) once-weekly, injectable glucagon-like peptide-1 (GLP-1) receptor agonist approved to improve blood sugar (glucose) in adults with type 2 diabetes. Trulicity should be used along with diet and exercise.

"I've seen in my practice that even with effective oral medicines like SGLT-2 inhibitors and metformin, many adults with type 2 diabetes may still need additional therapy to maintain their blood sugar levels," said Bernhard Ludvik, M.D., associate professor of medicine, Rudolfstiftung Hospital Vienna and AWARD-10 lead author. "The AWARD-10 results suggest that the combination of once-weekly Trulicity and an SGLT-2 inhibitor shows significant promise in helping more people with type 2 diabetes reach their treatment goals."

At the study's primary endpoint of 24 weeks, both Trulicity 1.5 mg and 0.75 mg added to ongoing treatment with an SGLT-2 inhibitor demonstrated statistically superior glycemic control (-1.34 percent, -1.21 percent for Trulicity 1.5 mg and 0.75 mg, respectively) compared to an SGLT-2 inhibitor with placebo (-0.54 percent). Further, significantly more people in the Trulicity groups reached target A1C levels of less than 7 percent and less than or equal to 6.5 percent:1

  • Trulicity 1.5 mg: 71 percent ( < 7 percent); 50 percent (≤6.5 percent)
  • Trulicity 0.75 mg: 60 percent ( < 7 percent); 38 percent (≤6.5 percent)
  • Placebo: 32 percent ( < 7 percent); 14 percent (≤6.5 percent)

Additional results showed that Trulicity 1.5 mg combined with an SGLT-2 inhibitor was associated with greater average weight loss (-3.1 kg) compared to placebo (-2.1 kg). An average weight reduction of -2.6 kg was seen in the Trulicity 0.75 mg group.

The most commonly reported adverse events associated with Trulicity were gastrointestinal-related and consistent with previous studies. Nausea (15 percent, 5 percent, 4 percent), vomiting (4 percent, 3 percent, 1 percent) and diarrhea (6 percent, 10 percent, 3 percent) were more frequent in the Trulicity 1.5 mg and 0.75 mg groups compared to placebo. One severe hypoglycemic event was documented in the Trulicity 0.75 mg group. No new Trulicity-related safety concerns were identified.1

"Managing type 2 diabetes with diet, exercise and oral medications may require the addition of injectable therapy for some people, given the progressive nature of the disease," said Brad Woodward, M.D., senior medical director, Lilly Diabetes. "AWARD-10 showed that Trulicity, when used in combination with an SGLT-2 inhibitor and metformin, may be effective and well tolerated in people with type 2 diabetes."  

About the AWARD-10 Study
The Phase 3b, double-blind, parallel-arm, placebo-controlled, 24-week AWARD-10 study compared the safety and efficacy of Trulicity 1.5 mg and 0.75 mg in combination with sodium glucose co-transporter-2 (SGLT-2) inhibitors to placebo plus SGLT-2 inhibitors in people with type 2 diabetes inadequately controlled with SGLT-2 inhibitors, with or without metformin. The primary objective of this study, in 424 patients in eight countries with a mean baseline A1C of 8.04 percent, was to demonstrate superiority of Trulicity plus an SGLT-2 inhibitor to placebo plus an SGLT-2 inhibitor on A1C reduction.

Indication and Limitations of Use for Trulicity®
Trulicity is a once-weekly injectable prescription medicine to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It should be used along with diet and exercise. Trulicity is not recommended as the first medication to treat diabetes. It has not been studied in people who have had inflammation of the pancreas (pancreatitis). Trulicity should not be used by people with type 1 diabetes, people with diabetic ketoacidosis, or people with a history of severe gastrointestinal (GI) disease. It is not a substitute for insulin. It has not been studied in children under 18 years of age.

About Diabetes
Approximately 30 million Americans2 and an estimated 425 million adults worldwide have diabetes.3 Type 2 diabetes is the most common type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases in the United States alone.2 Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research, collaboration and quality manufacturing we strive to make life better for people affected by diabetes. We offer a wide range of therapies and a continued determination to provide real solutions—from medicines and technologies to support programs and more. For the latest updates, visit or follow us on Twitter: @LillyDiabetes and Facebook: LillyDiabetesUS.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at and

1. Ludvik, Bernhard, MD, Frias, Juan P., MD, et. al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. 2018: S2213-8587 (18) 30023-8. Retrieved from
2. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Available at: November 2017.
3. International Diabetes Federation. IDF Diabetes Atlas, 8th edn, 2017. Available at: November 2017.

SOURCE: Eli Lilly

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up